ArticleJournal of lipid research2018
HDL functionality and cardiovascular outcome among nondialysis chronic kidney disease patients.
Article in Journal of lipid research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Cholesterol Efflux Capacity and Anti-Oxidative Activity of High-Density Lipoprotein in Chronic Kidney Disease.Journal of atherosclerosis and thrombosis · 2026Observational
- High density lipoprotein particle size and function associate with new cardiovascular events in patients with chronic kidney disease.PloS one · 2025Article
- The importance of paraoxonase 1 activity in chronic kidney disease.Renal failure · 2024Review
- Preeclampsia Affects Lipid Metabolism and HDL Function in Mothers and Their Offspring.Antioxidants (Basel, Switzerland) · 2023Article
- Low HDL Cholesterol Efflux Capacity Indicates a Fatal Course of COVID-19.Antioxidants (Basel, Switzerland) · 2022Article
- High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad, and the Future II.Biomedicines · 2022Article
- Monocyte to HDL ratio: a novel marker of resistant hypertension in CKD patients.International urology and nephrology · 2022Article
- HDL and Kidney Diseases.Advances in experimental medicine and biology · 2022Article
- Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.Nature reviews. Nephrology · 2021Review
- Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.Cardiovascular drugs and therapy · 2021Review
- Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?Biomedicines · 2021Review
- Dietary Strategies to Improve Cardiovascular Health: Focus on Increasing High-Density Lipoprotein Functionality.Frontiers in nutrition · 2021Review
- Using Machine Learning to Evaluate the Role of Microinflammation in Cardiovascular Events in Patients With Chronic Kidney Disease.Frontiers in immunology · 2021Article
- Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease.Biomolecules · 2020Review
- Impaired Delivery of Cholesterol Effluxed From Macrophages to Hepatocytes by Serum From CKD Patients May Underlie Increased Cardiovascular Disease Risk.Kidney international reports · 2020Article
- The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease.International journal of molecular sciences · 2020Review
- Arylesterase Activity of HDL Associated Paraoxonase as a Potential Prognostic Marker in Patients With Sepsis and Septic Shock-A Prospective Pilot Study.Frontiers in medicine · 2020Article
- Kidney as modulator and target of "good/bad" HDL.Pediatric nephrology (Berlin, Germany) · 2019Review
- Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients.The Journal of clinical endocrinology and metabolism · 2019Article
- Longitudinal lipid trends and adverse outcomes in patients with CKD: a 13-year observational cohort study.Journal of lipid research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
CVD remains the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). CKD profoundly affects HDL composition and functionality, but whether abnormal HDL independently contributes to cardiovascular events in CKD patients remains elusive. In the present study, we assessed whether compositional and functional properties of HDL predict cardiovascular outcome among 526 nondialysis CKD patients who participate in the CARE FOR HOMe study. We measured HDL cholesterol, the content of HDL-associated proinflammatory serum amyloid A (SAA), and activities of the HDL enzymes paraoxonase and lipoprotein-associated phospholipase A2 (Lp-PLA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.